方建阳

l   研究方向：

Ø  聚焦疾病特异性生物标志物（癌症：FAP、PSMA、STING；细菌感染；无菌炎症），开发新型核素探针，用于疾病的诊疗研究；

Ø  多策略调控核素探针体内药代动力学性质，推动核素药物临床转化。

l   项目经历：主持第73批博士后面上项目（2023M742916），2024年入选国家博士后资助研究人员计划（GZC20240891），j9九游会人才启动项目。

l   教育工作经历

l   个人简介：主要从事新型放射性药物的设计研发及其在肿瘤精准诊疗中的转化应用研究。迄今以第一作者或通讯作者（含共同）身份在Acta   Pharmaceutica Sinica B、Journal   of Nuclear Medicine（3篇）、European Journal of Nuclear   Medicine and Molecular Imaging（2篇）、Journal of Controlled   Release（2篇）、Journal of Medicinal   Chemistry（5篇）、Molecular Pharmaceutics（2篇）等国际期刊发表论文17篇，其中TOP期刊论文13篇；申请发明专利10项，已授权5项，H-index为14。曾获第23届国际放射性药物科学大会（ISRS）旅行资助奖、第八届全国同位素制备及应用研讨会“青年优秀论文奖”及第五届分子影像学厦门论坛“青年学者奖”。在临床转化方面，作为工艺开发与质量控制负责人参与多项放射性创新药的IND申报，协助获得中国CDE及美国FDA新药临床试验批件，并在第二届全国博士后创新创业大赛福建省选拔赛中获前三名。

l   ResearchGate主页：https://www.researchgate.net/profile/Jianyang-Fang

l   联系邮箱：fangjy8228@fjmu.edu.cn

l   代表性论文（#：共同作者；*：共同通讯）

1.      Jianyang   Fang^#,   Lixia Feng^#,   Lingxin Meng^#, et   al., A novel ¹⁸F-labeled agonist for PET imaging of stimulator of   interferon gene expression in tumor-bearing mice, European Journal of   Nuclear Medicine and Molecular Imaging, 2022, 50(1): 27-37.

2.    Jianyang Fang^#,   Xiaobo Wang^#, Lingxin Meng, et al., Preclinical Evaluation of ¹³¹I/¹⁸F-Labeled   Covalent Small-Molecule Inhibitors for STING Status Imaging, ACS   Pharmacology & Translational Science.2024, 7(6): 1783-1794

3.    Jianyang Fang^#,   Jingru Zhang^#, Lingxin Meng, et al.,¹⁸F-Labeled Amidobenzimidazole Analogue for   Visualizing STING Expression in Tumor, Molecular Pharmaceutics. 2024, 21(4): 1942-1951.

4.    Lumei   Huang^#, Jianyang Fang^#,   Shouqiang Hong, et al., MicroPET imaging of bacterial infection with   nitroreductase-specific responsive ¹⁸F-labelled nitrogen mustard   analogues, European Journal of Nuclear Medicine and Molecular Imaging,   2022, 49(8): 2645-2654.

5.    Lingxin   Meng^#, Jianyang Fang^#,   Liang Zhao^#, et   al., Rational Design and Pharmacomodulation of Protein-Binding Theranostic   Radioligands for Targeting the Fibroblast Activation Protein, Journal of   Medicinal Chemistry, 2022, 65(12): 8245-8257.

6.    Lingxin   Meng^#, Jianyang Fang^#,   Jingru Zhang, et   al., Rational Design and Comparison of Novel ^99mTc-Labeled FAPI   Dimers for Visualization of Multiple Tumor Types,   Journal of Medicinal Chemistry.2024,

7.    Liang Zhao^#, Yizhen Pang^#,   Jianyang Fang^#, et al., Design, Preclinical Evaluation, and   Clinical Translation of ⁶⁸Ga-FAPI-LM3, a Heterobivalent Molecule   for PET Imaging of Nasopharyngeal Carcinoma, Journal of Nuclear Medicine,2024,   65(3): 394-401.

8.    Yizhen   Pang^#, Liang Zhao^#, Jianyang Fang^#,   et al., Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of   FAPI Radioligand Therapy. Journal of Nuclear Medicine, 2023, 64(9):   1449-1455.

9.    Liang   Zhao^#, Bo Niu^#, Jianyang Fang^#,   et al., Synthesis, preclinical evaluation, and a pilot clinical PET imaging   study of 68Ga-labeled FAPI dimer, Journal of Nuclear Medicine, 2022,   63(6): 862-868.

10.  Lingxin Meng^#, Jianyang Fang^#, Xiaoru Lin^#, et al. Developments of radioligands with an   albumin-binding moiety of 4-(P-Iodophenyl) butyric acid[J]. Journal of   Controlled Release, 2025: 113757.

11.  ……, Jianyang Fang*, Xianzhong Zhang*, and Zhide Guo*, Rational Design and Pharmacomodulation of ¹⁸F-Labeled   Biotin/FAPI-Conjugated Heterodimers,Journal of Medicinal Chemistry.2024,   67(10): 8361-8371.

12.  ……,   Jianyang Fang*, Weibing Miao*, and Zhide   Guo*, Modification of Asp–Peptide Adapters: Giving the FAP-Targeted   Radioligand a “Squirrel Tail”, Journal   of Medicinal Chemistry, 2025, 2025(6):68

13.  ……,   Jianyang Fang*, Xianzhong Zhang*, and   Zhide Guo*, FAP-targeted delivery of radioiodinated probes: A progressive   albumin-driven strategy for tumor theranostics[J]. Journal of Controlled Release, 2025: 113678.